VU University Medical Center, Amsterdam, the Netherlands;
Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich;
Research Laboratories of Schering AG, Berlin, Germany;
Istituto G. Gaslini, Genova, Italy
Objective: The human monoclonal antibody L19-SIP is directed against the extra domain B of fibronectin (ED-B), a marker of tumor angiogenesis. The potential of radioimmunotherapy (RIT) with L19-SIP was evaluated, either alone or in combination with the anti–epidermal growth factor receptor (EGFR) antibody cetuximab, for treatment of head and neck squamous cell carcinoma (HNSCC).